The Big Three PBMs’ 2023 Formulary Exclusions: Observations on Insulin, Humira, and Biosimilars (rerun)
Drug Channels
MARCH 28, 2023
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. Each exclusion list now contains about 600 products. d/b/a Drug Channels Institute. As always, I welcome your comments below or on social media.
Let's personalize your content